{
  "run": {
    "id": "cmnr13sxq03y7p658u3zxvy5v",
    "region": "US",
    "assetId": "cmnr13smt03xqp658qje4kdq1",
    "ticker": "GEHC",
    "snapshotId": "cmnr13sqw03xup658btgmz6nw",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:20:47.676Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr13sqw03xup658btgmz6nw",
      "assetId": "cmnr13smt03xqp658qje4kdq1",
      "asOf": "2026-04-08T20:00:02.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:02.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:02.000Z",
          "open": null,
          "price": 73.75,
          "dayLow": 72,
          "volume": 4579177,
          "dayHigh": 74.13,
          "currency": "USD",
          "prevClose": 69.73,
          "week52Low": 57.65,
          "week52High": 89.77
        },
        "fundamentals": {
          "pe": 17.9868421052632,
          "beta": 1.13478313155409,
          "epsTTM": 4.56,
          "fcfTTM": null,
          "growth": {
            "epsYoy": 0.04347826086956511,
            "revenueYoy": 0.04844448962993086
          },
          "sector": "X-Ray Apparatus & Tubes & Related Irradiation Apparatus",
          "margins": {
            "net": 0.1010424242424242,
            "gross": 0.3999030303030303,
            "operating": 0.1339636363636364
          },
          "website": "https://www.gehealthcare.com/",
          "industry": "Healthcare",
          "pegRatio": 4.13697368421053,
          "ebitdaTTM": 2800000000,
          "forwardPe": 16.6032388663968,
          "marketCap": 34000000000,
          "totalCash": 4492000000,
          "totalDebt": 10511000000,
          "debtEquity": 1.0127179882455,
          "quickRatio": 0.5037891268533773,
          "revenueTTM": 20625000000,
          "companyName": "GE HealthCare Technologies Inc.",
          "priceToBook": 3.528740447212,
          "currentRatio": 1.372981878088962,
          "dividendYield": 0.00171117870266987,
          "returnOnAssets": 0.05646778301631171,
          "returnOnEquity": 0.200790056845554,
          "analystOpinions": null,
          "businessSummary": "GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures contrast agents and radiopharmaceuticals.",
          "enterpriseValue": 43420120000,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": 54000,
          "sharesOutstanding": 455749767,
          "enterpriseToEbitda": 15.50718571428571,
          "analystTargetMedian": null,
          "enterpriseToRevenue": 2.105217939393939,
          "operatingCashflowTTM": 1987000000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:20:47.432Z"
    },
    "results": [
      {
        "id": "cmnr13sxs03yep658f5o57kqp",
        "runId": "cmnr13sxq03y7p658u3zxvy5v",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"GEHC\",\"currency\":\"USD\",\"current_price\":73.75,\"target_price_6m\":79.5,\"target_price_12m\":84.0,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Medtech leader trading below 52-week highs with margin expansion runway\",\"Forward P/E of ~16.6x is attractive vs healthcare equipment peers\",\"Operating margin at 13.4% has room to expand toward mid-to-high teens\",\"Significant installed base supports recurring service and upgrade revenue\",\"Elevated debt load and modest organic growth temper near-term upside\"],\"key_drivers\":[{\"driver\":\"Operating margin expansion from cost optimization and mix shift\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"AI-enabled imaging product cycle driving premium pricing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Recurring service revenue from large installed base\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pharmaceutical diagnostics segment growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Global hospital capex recovery post-COVID normalization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Net debt of ~$6B constraining capital allocation flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"PEG ratio of 4.1x signals valuation stretched relative to EPS growth\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Tariff and trade policy uncertainty on global supply chain\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"FX headwinds from strong USD on international revenue\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Tariff escalation could materially increase COGS and compress margins\",\"Revenue growth stalls below 4% if hospital spending weakens\",\"Debt refinancing at higher rates pressures interest expense\",\"Competitive pressure from Siemens Healthineers and Philips\",\"Regulatory changes to reimbursement reduce customer purchasing power\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.16,\"wacc\":0.095,\"terminal_multiple\":16.0},\"scenarios\":{\"bear\":{\"target_price\":62.0,\"prob\":0.2,\"notes\":\"Tariffs and macro slowdown compress margins; P/E contracts to 14x on ~$4.40 EPS.\"},\"base\":{\"target_price\":84.0,\"prob\":0.55,\"notes\":\"Mid-single-digit growth continues with modest margin expansion; ~17x on ~$4.95 EPS.\"},\"bull\":{\"target_price\":98.0,\"prob\":0.25,\"notes\":\"AI imaging cycle accelerates revenue; margins reach 16%+; P/E re-rates to ~18.5x.\"}},\"method_notes\":\"Valuation blends forward P/E (primary) and EV/EBITDA cross-check. Base case assumes ~$4.95 FY EPS on ~5% rev growth and ~100bps margin expansion, valued at ~17x forward P/E. EV/EBITDA of ~15.5x is near fair for medtech. 12M expected return of ~14% supports BUY. PEG ratio cautions against STRONG_BUY. High debt and tariff uncertainty reduce confidence. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "Tariff escalation could materially increase COGS and compress margins",
            "Revenue growth stalls below 4% if hospital spending weakens",
            "Debt refinancing at higher rates pressures interest expense",
            "Competitive pressure from Siemens Healthineers and Philips",
            "Regulatory changes to reimbursement reduce customer purchasing power"
          ],
          "ticker": "GEHC",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Mid-single-digit growth continues with modest margin expansion; ~17x on ~$4.95 EPS.",
              "target_price": 84
            },
            "bear": {
              "prob": 0.2,
              "notes": "Tariffs and macro slowdown compress margins; P/E contracts to 14x on ~$4.40 EPS.",
              "target_price": 62
            },
            "bull": {
              "prob": 0.25,
              "notes": "AI imaging cycle accelerates revenue; margins reach 16%+; P/E re-rates to ~18.5x.",
              "target_price": 98
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.095,
            "revenue_cagr_3y": 0.05,
            "terminal_multiple": 16,
            "ebit_margin_target": 0.16
          },
          "key_drivers": [
            {
              "driver": "Operating margin expansion from cost optimization and mix shift",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "AI-enabled imaging product cycle driving premium pricing",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Recurring service revenue from large installed base",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Pharmaceutical diagnostics segment growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Global hospital capex recovery post-COVID normalization",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Net debt of ~$6B constraining capital allocation flexibility",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "PEG ratio of 4.1x signals valuation stretched relative to EPS growth",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Tariff and trade policy uncertainty on global supply chain",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "FX headwinds from strong USD on international revenue",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation blends forward P/E (primary) and EV/EBITDA cross-check. Base case assumes ~$4.95 FY EPS on ~5% rev growth and ~100bps margin expansion, valued at ~17x forward P/E. EV/EBITDA of ~15.5x is near fair for medtech. 12M expected return of ~14% supports BUY. PEG ratio cautions against STRONG_BUY. High debt and tariff uncertainty reduce confidence. Not investment advice.",
          "current_price": 73.75,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Medtech leader trading below 52-week highs with margin expansion runway",
            "Forward P/E of ~16.6x is attractive vs healthcare equipment peers",
            "Operating margin at 13.4% has room to expand toward mid-to-high teens",
            "Significant installed base supports recurring service and upgrade revenue",
            "Elevated debt load and modest organic growth temper near-term upside"
          ],
          "target_price_6m": 79.5,
          "target_price_12m": 84
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 32580,
        "createdAt": "2026-04-09T05:20:47.676Z",
        "usage": {
          "inputTokens": 3637,
          "outputTokens": 1644,
          "costUsd": 0.059285
        }
      },
      {
        "id": "cmnr13sxs03yhp658q6ly6t2d",
        "runId": "cmnr13sxq03y7p658u3zxvy5v",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"Equity Research AI Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"GEHC\",\n  \"currency\": \"USD\",\n  \"current_price\": 73.75,\n  \"target_price_6m\": 74.5,\n  \"target_price_12m\": 76,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.6,\n  \"thesis_bullets\": [\"Steady demand in medical imaging supports revenue.\", \"Cost efficiencies may improve operating margins.\", \"Competitive landscape limits pricing power.\", \"Debt levels are manageable but require monitoring.\", \"Valuation appears fair with balanced risk-reward.\"],\n  \"key_drivers\": [\n    {\"driver\": \"Aging population driving imaging volume\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"AI integration in diagnostics\", \"impact\": \"MED\", \"direction\": \"POS\"},\n    {\"driver\": \"Regulatory approval delays\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n    {\"driver\": \"Supply chain stability\", \"impact\": \"LOW\", \"direction\": \"NEG\"},\n    {\"driver\": \"Geographic expansion in emerging markets\", \"impact\": \"MED\", \"direction\": \"POS\"},\n    {\"driver\": \"Intense competition from peers\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n    {\"driver\": \"Macroeconomic factors affecting healthcare spend\", \"impact\": \"MED\", \"direction\": \"NEG\"}\n  ],\n  \"risks\": [\"Economic recession impacting capital investment\", \"Foreign exchange volatility\", \"Technological disruption by new entrants\", \"Changes in healthcare reimbursement policies\"],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.05,\n    \"ebit_margin_target\": 0.14,\n    \"wacc\": 0.08,\n    \"terminal_multiple\": 14\n  },\n  \"scenarios\": {\n    \"bear\": {\"target_price\": 70, \"prob\": 0.2, \"notes\": \"Lower growth and margin pressure.\"},\n    \"base\": {\"target_price\": 76, \"prob\": 0.6, \"notes\": \"Steady execution on current plans.\"},\n    \"bull\": {\"target_price\": 82, \"prob\": 0.2, \"notes\": \"Accelerated adoption of new technologies.\"}\n  },\n  \"method_notes\": \"Valuation based on DCF with terminal multiple; HOLD due to fair value and mixed evidence. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "Equity Research AI Model",
          "risks": [
            "Economic recession impacting capital investment",
            "Foreign exchange volatility",
            "Technological disruption by new entrants",
            "Changes in healthcare reimbursement policies"
          ],
          "ticker": "GEHC",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady execution on current plans.",
              "target_price": 76
            },
            "bear": {
              "prob": 0.2,
              "notes": "Lower growth and margin pressure.",
              "target_price": 70
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated adoption of new technologies.",
              "target_price": 82
            }
          },
          "confidence": 0.6,
          "assumptions": {
            "wacc": 0.08,
            "revenue_cagr_3y": 0.05,
            "terminal_multiple": 14,
            "ebit_margin_target": 0.14
          },
          "key_drivers": [
            {
              "driver": "Aging population driving imaging volume",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "AI integration in diagnostics",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Regulatory approval delays",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Supply chain stability",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Geographic expansion in emerging markets",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Intense competition from peers",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Macroeconomic factors affecting healthcare spend",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation based on DCF with terminal multiple; HOLD due to fair value and mixed evidence. Not investment advice.",
          "current_price": 73.75,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Steady demand in medical imaging supports revenue.",
            "Cost efficiencies may improve operating margins.",
            "Competitive landscape limits pricing power.",
            "Debt levels are manageable but require monitoring.",
            "Valuation appears fair with balanced risk-reward."
          ],
          "target_price_6m": 74.5,
          "target_price_12m": 76
        },
        "errorsJson": {
          "attempts": [
            {
              "error": "provider_error: terminated",
              "attempt": 0,
              "rawOutputTruncated": null
            }
          ],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 356,
        "createdAt": "2026-04-09T05:20:47.676Z",
        "usage": {
          "inputTokens": 2133,
          "outputTokens": 3837,
          "costUsd": 0.002209
        }
      },
      {
        "id": "cmnr13sxs03yfp658jzrapiv3",
        "runId": "cmnr13sxq03y7p658u3zxvy5v",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"Equity Research Analyst AI\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"GEHC\",\"currency\":\"USD\",\"current_price\":73.75,\"target_price_6m\":81.0,\"target_price_12m\":88.0,\"recommendation\":\"BUY\",\"confidence\":0.72,\"thesis_bullets\":[\"Post-spin operational independence driving structural margin expansion through cost optimization.\",\"Leadership in high-growth molecular imaging and AI-enabled diagnostic software.\",\"Resilient recurring revenue streams from long-term service contracts and consumables.\",\"Deleveraging profile improves equity valuation as debt-to-EBITDA ratios normalize.\",\"Aging global demographics sustain long-term demand for advanced medical imaging.\"],\"key_drivers\":[{\"driver\":\"AI software adoption\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Hospital CapEx cycles\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"R&D efficiency\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Interest rate environment\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"China market recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Supply chain stability\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Intense pricing competition from global medtech peers.\",\"High leverage ratio relative to industry average.\",\"Regulatory delays for new product launches.\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.16,\"wacc\":0.085,\"terminal_multiple\":14.5},\"scenarios\":{\"bear\":{\"target_price\":65.0,\"prob\":0.2,\"notes\":\"Slower hospital spending and margin compression.\"},\"base\":{\"target_price\":88.0,\"prob\":0.6,\"notes\":\"Steady execution on margin targets.\"},\"bull\":{\"target_price\":102.0,\"prob\":0.2,\"notes\":\"Accelerated AI monetization and rapid deleveraging.\"}},\"method_notes\":\"Valuation derived from a blended P/E approach assuming 18x forward earnings. Recommendation reflects ~19% upside. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "Equity Research Analyst AI",
          "risks": [
            "Intense pricing competition from global medtech peers.",
            "High leverage ratio relative to industry average.",
            "Regulatory delays for new product launches."
          ],
          "ticker": "GEHC",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady execution on margin targets.",
              "target_price": 88
            },
            "bear": {
              "prob": 0.2,
              "notes": "Slower hospital spending and margin compression.",
              "target_price": 65
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated AI monetization and rapid deleveraging.",
              "target_price": 102
            }
          },
          "confidence": 0.72,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.05,
            "terminal_multiple": 14.5,
            "ebit_margin_target": 0.16
          },
          "key_drivers": [
            {
              "driver": "AI software adoption",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Hospital CapEx cycles",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "R&D efficiency",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Interest rate environment",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "China market recovery",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Supply chain stability",
              "impact": "LOW",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation derived from a blended P/E approach assuming 18x forward earnings. Recommendation reflects ~19% upside. Not investment advice.",
          "current_price": 73.75,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Post-spin operational independence driving structural margin expansion through cost optimization.",
            "Leadership in high-growth molecular imaging and AI-enabled diagnostic software.",
            "Resilient recurring revenue streams from long-term service contracts and consumables.",
            "Deleveraging profile improves equity valuation as debt-to-EBITDA ratios normalize.",
            "Aging global demographics sustain long-term demand for advanced medical imaging."
          ],
          "target_price_6m": 81,
          "target_price_12m": 88
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "model": "gemini-3-flash-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 18937,
        "createdAt": "2026-04-09T05:20:47.676Z",
        "usage": {
          "inputTokens": 2477,
          "outputTokens": 466,
          "costUsd": 0.010546
        }
      },
      {
        "id": "cmnr13sxs03ydp6580pn7eaet",
        "runId": "cmnr13sxq03y7p658u3zxvy5v",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"gpt-5\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"GEHC\",\"currency\":\"USD\",\"current_price\":73.75,\"target_price_6m\":75.5,\"target_price_12m\":77,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"Imaging and diagnostics franchises support resilient mid-single-digit revenue growth.\",\"Margins can improve through mix, productivity, and service attach expansion.\",\"Current valuation already discounts much of the near-term recovery.\",\"Balance sheet is manageable but leverage limits flexibility versus peers.\",\"Evidence is mixed: quality assets, but upside looks modest from snapshot price.\"],\"key_drivers\":[{\"driver\":\"Imaging equipment demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pharma Diagnostics growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Service and software mix\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Hospital capital budgets\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"China demand recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Input and freight costs\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Productivity programs\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Debt and rates burden\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Hospital capex delays\",\"China weakness persists\",\"Execution on margin expansion\",\"Regulatory or product issues\",\"FX headwinds\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.16,\"wacc\":0.09,\"terminal_multiple\":15},\"scenarios\":{\"bear\":{\"target_price\":62,\"prob\":0.25,\"notes\":\"Capital spending softens and margin gains stall.\"},\"base\":{\"target_price\":77,\"prob\":0.5,\"notes\":\"Mid-single-digit growth with modest margin expansion.\"},\"bull\":{\"target_price\":90,\"prob\":0.25,\"notes\":\"Imaging cycle strengthens and diagnostics outperforms.\"}},\"method_notes\":\"Blended earnings/multiple framework anchored to snapshot fundamentals and scenario-weighted 12M value; no sell-side targets used. HOLD fits ~4.4% 12M upside with mixed growth and valuation signals. not investment advice\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "gpt-5",
          "risks": [
            "Hospital capex delays",
            "China weakness persists",
            "Execution on margin expansion",
            "Regulatory or product issues",
            "FX headwinds"
          ],
          "ticker": "GEHC",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Mid-single-digit growth with modest margin expansion.",
              "target_price": 77
            },
            "bear": {
              "prob": 0.25,
              "notes": "Capital spending softens and margin gains stall.",
              "target_price": 62
            },
            "bull": {
              "prob": 0.25,
              "notes": "Imaging cycle strengthens and diagnostics outperforms.",
              "target_price": 90
            }
          },
          "confidence": 0.63,
          "assumptions": {
            "wacc": 0.09,
            "revenue_cagr_3y": 0.05,
            "terminal_multiple": 15,
            "ebit_margin_target": 0.16
          },
          "key_drivers": [
            {
              "driver": "Imaging equipment demand",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pharma Diagnostics growth",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Service and software mix",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Hospital capital budgets",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "China demand recovery",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Input and freight costs",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Productivity programs",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Debt and rates burden",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "Blended earnings/multiple framework anchored to snapshot fundamentals and scenario-weighted 12M value; no sell-side targets used. HOLD fits ~4.4% 12M upside with mixed growth and valuation signals. not investment advice",
          "current_price": 73.75,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Imaging and diagnostics franchises support resilient mid-single-digit revenue growth.",
            "Margins can improve through mix, productivity, and service attach expansion.",
            "Current valuation already discounts much of the near-term recovery.",
            "Balance sheet is manageable but leverage limits flexibility versus peers.",
            "Evidence is mixed: quality assets, but upside looks modest from snapshot price."
          ],
          "target_price_6m": 75.5,
          "target_price_12m": 77
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_044ce281179398400069d7595018d481978ca65094c3468f1e",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 18338,
        "createdAt": "2026-04-09T05:20:47.676Z",
        "usage": {
          "inputTokens": 2407,
          "outputTokens": 992,
          "costUsd": 0.0181
        }
      },
      {
        "id": "cmnr13sxs03ygp65860gh8alg",
        "runId": "cmnr13sxq03y7p658u3zxvy5v",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI DCF Valuation Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"GEHC\",\n  \"currency\": \"USD\",\n  \"current_price\": 73.75,\n  \"target_price_6m\": 79,\n  \"target_price_12m\": 85,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.62,\n  \"thesis_bullets\": [\n    \"Steady demand for core imaging and ultrasound\",\n    \"AI enhancements driving differentiation and pricing\",\n    \"Margin expansion from cost optimization initiatives\",\n    \"Demographic trends supporting long-term growth\",\n    \"Reasonable valuation with forward P/E at 16.6x\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"AI integration in diagnostics\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Hospital capex cycles\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Aging population healthcare spend\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Supply chain cost volatility\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Competition from Siemens/Philips\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Regulatory approval delays\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"International market expansion\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Interest rate effects on EV\",\n      \"impact\": \"LOW\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Intensifying competition in imaging\",\n    \"Hospital budget constraints\",\n    \"Margin expansion execution risk\",\n    \"Geopolitical supply chain issues\",\n    \"Currency volatility in global sales\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.055,\n    \"ebit_margin_target\": 0.155,\n    \"wacc\": 0.085,\n    \"terminal_multiple\": 15\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 62,\n      \"prob\": 0.25,\n      \"notes\": \"Prolonged hospital budget constraints and margin pressure.\"\n    },\n    \"base\": {\n      \"target_price\": 85,\n      \"prob\": 0.5,\n      \"notes\": \"Steady growth and modest margin improvement realized.\"\n    },\n    \"bull\": {\n      \"target_price\": 105,\n      \"prob\": 0.25,\n      \"notes\": \"Accelerated AI adoption drives above-trend sales.\"\n    }\n  },\n  \"method_notes\": \"DCF using 3y revenue CAGR, EBIT margin target, WACC and terminal multiple on snapshot fundamentals. Base case 15% upside supports BUY. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI DCF Valuation Model",
          "risks": [
            "Intensifying competition in imaging",
            "Hospital budget constraints",
            "Margin expansion execution risk",
            "Geopolitical supply chain issues",
            "Currency volatility in global sales"
          ],
          "ticker": "GEHC",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady growth and modest margin improvement realized.",
              "target_price": 85
            },
            "bear": {
              "prob": 0.25,
              "notes": "Prolonged hospital budget constraints and margin pressure.",
              "target_price": 62
            },
            "bull": {
              "prob": 0.25,
              "notes": "Accelerated AI adoption drives above-trend sales.",
              "target_price": 105
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.055,
            "terminal_multiple": 15,
            "ebit_margin_target": 0.155
          },
          "key_drivers": [
            {
              "driver": "AI integration in diagnostics",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Hospital capex cycles",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Aging population healthcare spend",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Supply chain cost volatility",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Competition from Siemens/Philips",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Regulatory approval delays",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "International market expansion",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Interest rate effects on EV",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF using 3y revenue CAGR, EBIT margin target, WACC and terminal multiple on snapshot fundamentals. Base case 15% upside supports BUY. Not investment advice.",
          "current_price": 73.75,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Steady demand for core imaging and ultrasound",
            "AI enhancements driving differentiation and pricing",
            "Margin expansion from cost optimization initiatives",
            "Demographic trends supporting long-term growth",
            "Reasonable valuation with forward P/E at 16.6x"
          ],
          "target_price_6m": 79,
          "target_price_12m": 85
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "2b4abe5b-94ba-9c80-ba9c-480f78f6d5e4",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 12085,
        "createdAt": "2026-04-09T05:20:47.676Z",
        "usage": {
          "inputTokens": 2740,
          "outputTokens": 3050,
          "costUsd": 0.05397
        }
      }
    ]
  }
}